NCT04929444 (VERTAP) is a NA clinical trial of Training on vertigo in Vertigo, sponsored by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina.

Who is sponsoring NCT04929444?

NCT04929444 is sponsored by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina.

What drugs are being tested in NCT04929444?

Interventions in NCT04929444: Training on vertigo.

What condition does NCT04929444 study?

NCT04929444 studies Vertigo, Vertigo, Paroxysmal.

Is NCT04929444 still recruiting?

NCT04929444 is currently status unknown. Last updated 18 June 2021.

Last reviewed 2021-06-18 · How we verify

NCT04929444: VERTAP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Training to Improve Vertigo Management in Primary Care

Status unknown NA Last updated 18 June 2021

What this trial tests

NA trial testing Training on vertigo in Vertigo in 20 participants. Status unknown.

Timeline

1 September 2021

Primary endpoint
1 September 2021

31 December 2022

Quick facts

Lead sponsor	Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	1 September 2021
Primary completion	1 September 2021
Estimated completion	31 December 2022

Drugs / interventions tested

Training on vertigo

Conditions studied

Vertigo — all drugs for Vertigo →
Vertigo, Paroxysmal — all drugs for Vertigo, Paroxysmal →

Sponsor

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina — full company profile →

Who can join

15 and older, any sex, with Vertigo or Vertigo, Paroxysmal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objectives: To verify the effectiveness of a blended course in PC to improve adherence to clinical practice guidelines. Design: randomized community trial, by clusters (control group -CG- / intervention group -IG-) Scope: 20 PCT (primary care teams)(10 per group) Outcome variables will be: Diagnostic records (proportion of nonspecific diagnoses such as dizziness and vertigo, with respect to specific diagnoses such as BPPV, vestibular neuritis); Derivations to otorhinolaryngologist (ENT) and neurologist; Prescription of antivertiginous medications and Number of days off work caused by vertigo-related. Statistical analysis:Descriptive statistics of all the baseline variables will be carried out and, the differences between groups in the post-intervention outcome variables will be evaluated through the t-test. In the IG, a multivariate logistic regression model will identify response patterns based on the baseline variables of professionals and centers

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Effectiveness of a training intervention to improve the management of vertigo in primary care: a multicentre cluster-randomised trial, VERTAP.
Patiño JEP, Moreno JLB, Matos YR, Ortega JA, et al · · 2022 · cited 6× · PMID 35906606 · DOI 10.1186/s13063-022-06548-7
Effectiveness of training on vertigo/dizziness coding in primary care: a community-based cluster-randomized trial.
Perez-Patiño J, Cunillera-Puértolas O, Sanllorente-Melenchón A, Rando-Matos Y, et al · · 2026 · PMID 42260492 · DOI 10.1186/s12909-026-09645-2
Effectiveness of a training intervention to improve the management of vertigo in primary care: a multicentre cluster-randomized trial.
Patiño JEP, Moreno JLB, Matos YR, Ortega JA, et al · · 2022 · DOI 10.21203/rs.3.rs-1134130/v1

Verify or expand the search:

Other recruiting trials for Vertigo

Currently open trials in the same condition.

NCT07518069 — Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes · recruiting
NCT07299487 — Diagnostic Aid for Vertigo Patients · recruiting
NCT06738823 — Effect of Wii Fit Training in Comparison to Vestibular Rehabilitation Training on Balance in Patients With Benign Paroxy · NA · recruiting
NCT06321341 — Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied · Phase 4 · recruiting
NCT06062368 — Reducing Vertigo Associated With MRI Machines · NA · recruiting

Other Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina trials

Trials by the same sponsor.

NCT07441759 — throMboembolic Risk Associated To High atrIal Fibrillation riSk · not yet recruiting
NCT07132632 — Effect of a Multicomponent Therapeutic Exercise Program in Primary Care on Frailty and Sarcopenia in Older Adults · NA · not yet recruiting
NCT07373119 — Improving Frailty in Patients With Stable Ischemic Heart Disease · NA · enrolling by invitation
NCT06581367 — Tailoring Antibiotic Duration for Respiratory Tract Infections in Primary Care · Phase 4 · not yet recruiting
NCT06988904 — ENERGY2MOB STUDY: OBESITY MANAGEMENT IN BERGUEDÀ · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04929444 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Last refreshed: 18 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04929444.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing